{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"23.1","value":"8.0"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"20.3","value":"7.1"},{"groupId":"OG002","lowerLimit":"2.0","upperLimit":"14.3","value":"5.5"},{"groupId":"OG003","lowerLimit":"0.3","upperLimit":"20.3","value":"7.0"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"19.6","value":"7.3"},{"groupId":"OG005","lowerLimit":"1.8","upperLimit":"14.8","value":"8.4"}]}],"title":"Duration of survival follow up, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"33.2","value":"12.3"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"29.3","value":"8.4"},{"groupId":"OG002","lowerLimit":"2.0","upperLimit":"22.1","value":"14.3"},{"groupId":"OG003","lowerLimit":"0.3","upperLimit":"29.3","value":"8.5"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"27.7","value":"7.3"},{"groupId":"OG005","lowerLimit":"1.8","upperLimit":"23.1","value":"8.5"}]}],"title":"Duration of survival follow up, 36 months (DCO: Dec 11, 2020)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"23.1","value":"12.5"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"20.3","value":"8.4"},{"groupId":"OG002","lowerLimit":"2.0","upperLimit":"14.3","value":"14.3"},{"groupId":"OG003","lowerLimit":"0.3","upperLimit":"20.3","value":"8.4"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"19.6","value":"7.8"},{"groupId":"OG005","lowerLimit":"1.8","upperLimit":"14.8","value":"8.5"}]}],"title":"Overall survival, 25 months (DCO: Nov 8, 2019)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.4","upperLimit":"33.2","value":"12.6"},{"groupId":"OG001","lowerLimit":"0.3","upperLimit":"29.3","value":"8.6"},{"groupId":"OG002","lowerLimit":"2.0","upperLimit":"22.1","value":"14.3"},{"groupId":"OG003","lowerLimit":"0.3","upperLimit":"29.3","value":"8.9"},{"groupId":"OG004","lowerLimit":"0.2","upperLimit":"27.7","value":"7.8"},{"groupId":"OG005","lowerLimit":"1.8","upperLimit":"23.1","value":"8.5"}]}],"title":"Overall survival, 36 months (DCO: Dec 11, 2020)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"62"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"22"}],"units":"Participants"}],"description":"Duration of survival follow-up (months) was defined as the date of last contact - date of randomization/ registration + 1.Overall Survival (OS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause.","dispersionType":"Full Range","groups":[{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive DS-8201a once every 3 weeks.","id":"OG000","title":"DS-8201a"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive irinotecan monotherapy as prescribed by the physician before enrollment.","id":"OG001","title":"Physician's Choice Irinotecan"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG002","title":"Physician's Choice Paclitaxel"},{"description":"Participants with HER2-overexpressing (IHC 3+ or IHC 2+/ISH+) advanced gastric or gastroesophageal junction adenocarcinoma, whose disease had progressed on two prior regimens, were randomized to receive either irinotecan or paclitaxel monotherapy as prescribed by the physician before enrollment.","id":"OG003","title":"Physician's Choice Overall"},{"description":"Non-randomized participants with HER2 IHC 2+/ISH- advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every three weeks.","id":"OG004","title":"Exploratory: Naïve HER2 IHC 2+/ISH-, DS-8201a"},{"description":"Non-randomized participants with HER2 IHC 1+ advanced gastric or gastroesophageal junction adenocarcinoma who received DS-8201a once every 3 weeks.","id":"OG005","title":"Exploratory: Naïve HER2 IHC 1+, DS-8201a"}],"paramType":"MEDIAN","populationDescription":"Duration of survival and overall survival were assessed in the Intent-to-Treat Analysis Set.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of death (due to any cause), up to 36 months postdose","title":"Overall Survival Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set)","type":"SECONDARY","unitOfMeasure":"months"}